AIMS: We measured the association between a history of incarceration and HIV positivity among people who inject drugs (PWID) across Europe. DESIGN, SETTING AND PARTICIPANTS: This was a cross-sectional, multi-site, multi-year propensity-score matched analysis conducted in Europe. Participants comprised community-recruited PWID who reported a recent injection (within the last 12 months). MEASUREMENTS: Data on incarceration history, demographics, substance use, sexual behavior and harm reduction service use originated from cross-sectional studies among PWID in Europe. Our primary outcome was HIV status. Generalized linear mixed models and propensity-score matching were used to compare HIV status between ever- and never-incarcerated PWID. FINDINGS: Among 43 807 PWID from 82 studies surveyed (in 22 sites and 13 countries), 58.7% reported having ever been in prison and 7.16% (n = 3099) tested HIV-positive. Incarceration was associated with 30% higher odds of HIV infection [adjusted odds ratio (aOR) = 1.32, 95% confidence interval (CI) = 1.09-1.59]; the association between a history of incarceration and HIV infection was strongest among PWID, with the lowest estimated propensity-score for having a history of incarceration (aOR = 1.78, 95% CI = 1.47-2.16). Additionally, mainly injecting cocaine and/or opioids (aOR = 2.16, 95% CI = 1.33-3.53), increased duration of injecting drugs (per 8 years aOR = 1.31, 95% CI = 1.16-1.48), ever sharing needles/syringes (aOR = 1.91, 95% CI = 1.59-2.28) and increased income inequality among the general population (measured by the Gini index, aOR = 1.34, 95% CI = 1.18-1.51) were associated with a higher odds of HIV infection. Older age (per 8 years aOR = 0.84, 95% CI = 0.76-0.94), male sex (aOR = 0.77, 95% CI = 0.65-0.91) and reporting pharmacies as the main source of clean syringes (aOR = 0.72, 95% CI = 0.59-0.88) were associated with lower odds of HIV positivity. CONCLUSIONS: A history of incarceration appears to be independently associated with HIV infection among people who inject drugs (PWID) in Europe, with a stronger effect among PWID with lower probability of incarceration.
- Klíčová slova
- Europe, HIV, PWID, incarceration, injection drug use, prison,
- MeSH
- HIV infekce * epidemiologie MeSH
- HIV séropozitivita * MeSH
- intravenózní abúzus drog * epidemiologie MeSH
- lidé MeSH
- průřezové studie MeSH
- tendenční skóre MeSH
- uživatelé drog * MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
BACKGROUND AND AIMS: Despite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the historical development of successful epidemiological indicators and to present a framework for extending them with additional indicators of coverage and quality of harm reduction services, for monitoring and evaluation at international, national or subnational levels. The ultimate aim is to improve these services in order to reduce health and social problems among people who use drugs, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection, crime and legal problems, overdose (death) and other morbidity and mortality. METHODS AND RESULTS: The framework was developed collaboratively using consensus methods involving nominal group meetings, review of existing quality standards, repeated email commenting rounds and qualitative analysis of opinions/experiences from a broad range of professionals/experts, including members of civil society and organisations representing people who use drugs. Twelve priority candidate indicators are proposed for opioid agonist therapy (OAT), needle and syringe programmes (NSP) and generic cross-cutting aspects of harm reduction (and potentially other drug) services. Under the specific OAT indicators, priority indicators included 'coverage', 'waiting list time', 'dosage' and 'availability in prisons'. For the specific NSP indicators, the priority indicators included 'coverage', 'number of needles/syringes distributed/collected', 'provision of other drug use paraphernalia' and 'availability in prisons'. Among the generic or cross-cutting indicators the priority indicators were 'infectious diseases counselling and care', 'take away naloxone', 'information on safe use/sex' and 'condoms'. We discuss conditions for the successful development of the suggested indicators and constraints (e.g. funding, ideology). We propose conducting a pilot study to test the feasibility and applicability of the proposed indicators before their scaling up and routine implementation, to evaluate their effectiveness in comparing service coverage and quality across countries. CONCLUSIONS: The establishment of an improved set of validated and internationally agreed upon best practice indicators for monitoring harm reduction service will provide a structural basis for public health and epidemiological studies and support evidence and human rights-based health policies, services and interventions.
- Klíčová slova
- Best practice, Coverage, Drug services, Epidemiology, Evidence-based, HCV, HIV, Harm reduction, Indicators, Injecting drug users/IDU, Interventions, Knowledge exchange, Monitoring, People who inject drugs/PWID, People who use drugs/PWUD, Substance abuse,
- MeSH
- konsensus MeSH
- kvalita zdravotní péče * MeSH
- lidé MeSH
- poruchy spojené s užíváním psychoaktivních látek terapie MeSH
- snížení rizika poškození * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
Hepatitis B virus (HBV) infection is prevalent worldwide and is a significant cause of morbidity and mortality. This article describes the trend in HBV occurrence in Estonia from 1990 to 2005 in Estonia, with the aim of highlighting key determinants in transmission dynamics, risk groups, and possible implications for prevention and control. A marked increase in reported numbers of new HBV cases occurred in mid 1990s (reaching 39 per 100,000 population) and decline thereafter. We present data on HBV prevalence from different population groups (persons with verified sexually transmitted infection, prisoners, medical personnel, blood donors and injection drug users). Special vaccination programmes introduced in Estonia have been successful in the prevention of HBV, however, we suggest that the main risk groups such as injection drug users (IDUs), men having sex with men (MSM) and HIV infected persons should be actively encompassed into HBV vaccination programme.
- MeSH
- hepatitida B epidemiologie prevence a kontrola přenos MeSH
- homosexualita mužská MeSH
- intravenózní abúzus drog komplikace epidemiologie MeSH
- lidé MeSH
- prevalence MeSH
- rizikové faktory MeSH
- sexuálně přenosné nemoci komplikace epidemiologie MeSH
- vakcína proti hepatitidě B aplikace a dávkování MeSH
- vězni MeSH
- zdravotnický personál MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Estonsko epidemiologie MeSH
- Názvy látek
- vakcína proti hepatitidě B MeSH
The assessment of quality of life is central to understanding how people's lives are affected by HIV infection. Estonia--the smallest of three Baltic countries--has experienced massive outbreak of HIV infection. Yet, little is known about the quality of life of HIV infected people in Estonia. The purposes of the present study were to adapt the World Health Organization's Quality of life HIV instrument (WHOQoL-HIV) into Estonian setting and to assess the quality of life in a sample of HIV-infected persons in Estonia.
- MeSH
- AIDS komplikace MeSH
- dlouhodobě přežívající nosiči HIV * MeSH
- intravenózní abúzus drog MeSH
- kvalita života * MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nezaměstnanost MeSH
- průzkumy a dotazníky MeSH
- společenská třída MeSH
- Check Tag
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Estonsko MeSH
